2018-03-21 22:34:36GSK, PFE   - $36.27
-0.06 (-0.17%) … 22:3403/21/18 03/2122:34 03/21/1822:34 | GlaxoSmithKline in lead to buy Pfizer consumer unit, FT saysWith Reckitt Benckiser (RBGLY) already having confirmed it is out of the bidding for Pfizer's (PFE) Consumer Healthcare unit, stating that an acquisition for the whole business "did not fit" its acquisition criteria and an acquisition of part of the business "was not possible," GlaxoSmithKline (GSK) is in pole position to buy the owner of the Advil and Centrum brands, according to Financial Times. Pfizer has said it was considering a sale or spinoff of the business, or it could still decide to keep the division, the report added. Reference Link GSK PFE - $36.27
-0.06 (-0.17%) RBGLY - $16.14
0.18 (1.13%) | |
|---|
- 01/22/18
- WBLR
01/22/18
NO CHANGEWBLR
Outperform Dynavax has sold off 30% since Heplisav approval, says William Blair Dynavax (DVAX) shares have pulled back about 30% since the U.S. approval of Heplisav, the first and only two-dose hepatitis B vaccine that has demonstrated "superiority in efficacy and comparability" in safety to the standard of care, GlaxoSmithKline's (GSK) Engerix-B, William Blair analyst Katherine Xu tells investors in a research note. The analyst attributes the selloff to Dynavax electing to launch Heplisav on its own and the Street having insufficient confidence in the launch. She believes Heplisav has peak U.S. sales prospects of $600M and "provides a valuation floor." Xu also sees catalysts on the oncology side of the business. She maintains an Outperform rating on Dynavax with a $40 per share fair value estimate. - 01/22/18
- WELS
01/22/18
NO CHANGEWELS
Underperform Teva can't afford more pipeline setbacks, says Wells Fargo After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares. - 02/08/18
- MSCO
02/08/18
NO CHANGEMSCO
Equal Weight Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares. - 02/22/18
- LEER
Rapid adoption of Gilead Biktarvy to challenge GlaxoSmithKline outlook, says Leerink Leerink analyst Seamus Fernandez notes he has recently completed a MEDACorp survey of U.S. HIV treatment specialists and has found "impressively positive" sentiment about Gilead's (GILD) Biktarvy which seems likely to put sustained pressure on GlaxoSmithKline's (GSK) leading integrase inhibitor Tivicay, as well as cannibalizing Gilead's other combination and component products. - $36.27
-0.06 (-0.17%) - 12/05/17
- SBSH
12/05/17
NO CHANGETarget $72
SBSH
Buy Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47. - 01/29/18
- RHCO
01/29/18
NO CHANGETarget $40
RHCO
Hold Pfizer price target raised to $40 from $33 at SunTrust SunTrust analyst John Boris raised his price target on Pfizer to $40 and kept his Hold rating ahead of this week's earnings. The analyst attributes the price outlook revision to the positive impact of the tax changes, but notes that "transformative large-scale M&A" is needed to bring about return to "robust" long-term growth. - 02/07/18
- HCWC
02/07/18
NO CHANGETarget $31
HCWC
Buy Achaogen price target raised to $31 from $25 at H.C. Wainwright H.C. Wainwright analyst Ed Arce raised his price target for Achaogen (AKAO) to $31 after the FDA classified the outcome of its Q4 reinspection of Pfizer's (PFE) McPherson, Kansas facility as Voluntary Action Indicated. The news provides a clear regulatory path for approval of plazomicin out of the McPherson facility, Arce tells investors in a research note. He views the outcome as an "important risk-reducing development" that removes an overhang on Achaogen shares. The analyst keeps a Buy rating on the name. - 02/16/18
- SBSH
02/16/18
NO CHANGETarget $78
SBSH
Buy Three developments make Pfizer buying Bristol-Myers more likely, says Citi Citi analyst Andrew Baum raised his price target for Bristol-Myers Squibb (BMY) to $78 from $72 saying three developments over the last week have increased the probability of a Pfizer (PFE) takeover to near 65% from 50%. Bristol closed yesterday up $3.64, or 5.6%, to $68.98. First, Bristol's revenue potential in non-small cell lung cancer is partly de-risked through Checkmate-227 tumor mutation burden data, Baum tells investors in a research note. Second, the NKTR-214 development collaboration and equity stake in Nektar Therapeutics (NKTR) could materially increase Bristol's Opdivo market share, the analyst adds. And third, he believes Pfizer's immuno-oncology efforts "are looking increasingly suspect." Bristol-Myers is likely Pfizer's last chance to have a meaningful position in the $50B-plus per annum immuno-oncology market, Baum contends. He reiterates a Buy rating on Bristol shares. - $16.14
0.18 (1.13%) - 07/06/17
- JEFF
07/06/17
DOWNGRADEJEFF
Hold Reckitt Benckiser downgraded to Hold from Buy at Jefferies Jefferies analyst Martin Deboo downgraded Reckitt Benckiser to Hold saying the recent share rally no longer leaves sufficient upside for a Buy rating. The analyst raised his price target to 8,400p from 7,750p. |